tetano
Editor, Senior Moderator
J Infect Chemother
. 2023 Oct 20:S1341-321X(23)00262-3.
doi: 10.1016/j.jiac.2023.10.017. Online ahead of print. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis
Chihiro Shiraishi[SUP] 1 [/SUP], Hideo Kato[SUP] 2 [/SUP], Mao Hagihara[SUP] 3 [/SUP], Nobuhiro Asai[SUP] 4 [/SUP], Takuya Iwamoto[SUP] 1 [/SUP], Hiroshige Mikamo[SUP] 5 [/SUP]
Affiliations
Introduction: Baloxavir marboxil (BXM), a newly developed cap-dependent endonuclease inhibitor, is widely used to treat influenza virus infections in inpatients and outpatients. A previous meta-analysis included only outpatients and patients suspected of having an influenza virus infection based on clinical symptoms. However, whether BXM or oseltamivir is safer and more effective for inpatients remains controversial. Therefore, we conducted a systematic review and meta-analysis validating the effectiveness and safety of BXM versus oseltamivir in inpatients with influenza virus.
Methods: The Scopus, EMBASE, PubMed, Ichushi, and CINAHL databases were systematically searched for articles published until January 2023. The outcomes were mortality, hospitalization period, incidence of BXM- or oseltamivir-related adverse events, illness duration, and changes of virus titers and viral RNA load in patients with influenza virus infections.
Results: Two randomized controlled trials with 1624 outpatients and two retrospective studies with 874 inpatients were enrolled. No deaths occurred in outpatients treated with BXM or oseltamivir. Among inpatients, BXM reduced mortality (p = 0.06) and significantly shortened hospitalization period (p = 0.01) compared to oseltamivir. In outpatients, BXM had a significantly lower incidence of adverse events (p = 0.03), reductions in influenza virus titers (p < 0.001) and viral RNA loads (p < 0.001), and a tendency to be a shorter illness duration compared with that of oseltamivir (p = 0.27).
Conclusions: Our meta-analysis showed that BXM was safer and more effective in patients than oseltamivir; thus, supporting the use of BXM for the initial treatment of patients with proven influenza virus infection.
Keywords: Baloxavir marboxil; Influenza virus; Meta-analysis; Oseltamivir.
. 2023 Oct 20:S1341-321X(23)00262-3.
doi: 10.1016/j.jiac.2023.10.017. Online ahead of print. Comparison of clinical efficacy and safety of baloxavir marboxil versus oseltamivir as the treatment for influenza virus infections: A systematic review and meta-analysis
Chihiro Shiraishi[SUP] 1 [/SUP], Hideo Kato[SUP] 2 [/SUP], Mao Hagihara[SUP] 3 [/SUP], Nobuhiro Asai[SUP] 4 [/SUP], Takuya Iwamoto[SUP] 1 [/SUP], Hiroshige Mikamo[SUP] 5 [/SUP]
Affiliations
- PMID: 37866622
- DOI: 10.1016/j.jiac.2023.10.017
Introduction: Baloxavir marboxil (BXM), a newly developed cap-dependent endonuclease inhibitor, is widely used to treat influenza virus infections in inpatients and outpatients. A previous meta-analysis included only outpatients and patients suspected of having an influenza virus infection based on clinical symptoms. However, whether BXM or oseltamivir is safer and more effective for inpatients remains controversial. Therefore, we conducted a systematic review and meta-analysis validating the effectiveness and safety of BXM versus oseltamivir in inpatients with influenza virus.
Methods: The Scopus, EMBASE, PubMed, Ichushi, and CINAHL databases were systematically searched for articles published until January 2023. The outcomes were mortality, hospitalization period, incidence of BXM- or oseltamivir-related adverse events, illness duration, and changes of virus titers and viral RNA load in patients with influenza virus infections.
Results: Two randomized controlled trials with 1624 outpatients and two retrospective studies with 874 inpatients were enrolled. No deaths occurred in outpatients treated with BXM or oseltamivir. Among inpatients, BXM reduced mortality (p = 0.06) and significantly shortened hospitalization period (p = 0.01) compared to oseltamivir. In outpatients, BXM had a significantly lower incidence of adverse events (p = 0.03), reductions in influenza virus titers (p < 0.001) and viral RNA loads (p < 0.001), and a tendency to be a shorter illness duration compared with that of oseltamivir (p = 0.27).
Conclusions: Our meta-analysis showed that BXM was safer and more effective in patients than oseltamivir; thus, supporting the use of BXM for the initial treatment of patients with proven influenza virus infection.
Keywords: Baloxavir marboxil; Influenza virus; Meta-analysis; Oseltamivir.